|[February 04, 2013]
Agilent Technologies Introduces Updated Designer Drug and Oral Fluid Compendiums, Plus Expanded Drug Compound Library for Forensics and Toxicology
SANTA CLARA, Calif. --(Business Wire)--
Agilent Technologies (News - Alert) Inc. (NYSE: A) today introduced new application
compendiums on designer drug testing and toxicology of oral fluids.
Also available is an expanded GC/MS Designer Drug Library. The only
resource of its kind, this searchable library includes designer
stimulants that are often marketed as "bath salts" as well as additional
In tandem with the release of these new resources, Agilent is sponsoring
monthly webinars featuring industry experts who will discuss new LC/MS
and MS applications for forensic detection and analysis of designer
drugs and metabolites.
"Designer drugs-especially bath salts-continue to make headlines across
the country," said Tom Gluodenis, Agilent's global marketing manager of
Forensics and Toxicology. "The important resources we're introducing
today, used in collaboration with our specialized GC/MS laboratory
technologies, provide forensic practitioners, crime laboratories, and
federal workplace drug-testing programs with cost-effective, end-to-end
solutions for designer drug screening and analysis."
Designer drugs are formulated to get around existing definitions of
illicit compounds. Once difficult to trace, these substances can now be
quickly identified and analyzed using Agilent's GC/MS technologies.
Agilent's expanded application compendium, "Identification of Synthetic
Cannabinoids in Herbal Incense Blends by GC/MS," contains information on
45 cannabinoids and describes how to facilitate rapid screening and
identification of these marijuana-like compounds. A companion
compendium, "Analysis of Designer Stimulants by GC/MS," describes the
analysis of 30 stimulants.
Agilent developed these compendiums, and the expanded GC/MS Designer
Drug Library, in collaboration with NMS Labs.
Screening oral fluid is an accurate and effective alternative to
screening urine or blood. It provides many collection advantages, and
samples can be more easily analyzed using highly sensitive enzyme
immunoassays and LC-MS/MS instrumentation. Agilent's updated oral fluid
compendium, "Drugs and Metabolites in Oral Fluid: Immunoassay Screening
and LC/MS/MS Confirmation and Quantification," is a comprehensive
treatise on the detection of drugs of abuse in oral fluid, covering 100
drugs in 11 classes.
The compendium includes information on sample collection and
preparation, immunoassay screening and LC/QQQ confirmation. It also
reflects changes to the mandatory guidelines for Federal Workplace Drug
Testing Programs, and contains protocols for all the newly recommended
Schedule II prescription medications. Agilent developed the compendium
in collaboration with Immunlysis Corp.
To download the application compendium "Drugs and Metabolites in Oral
Fluid," visit Agilent's Forensics
& Toxicology website.
Webinar Series for Forensic Practitioners
Throughout the year, Agilent will sponsor a monthly online educational
series focusing on the analysis of designer drugs and drugs of abuse.
Hosted by RTI International's online education service on www.ForensicEd.org,
the webinars listed below will also be available for replay following
the live events. Additional webinars will be announced at a later date.
Comprehensive Workflow for Screening and Confirmation of Drugs in
Oral Fluids, now accessible for replay at Forensic
Science Education: Dr. Christine Moore of Immunalysis Corp.
discusses designer drug compendiums, oral fluids sample collection,
preparation, drug extraction, immunoassay screening and LC/QQQ
LC/QQQ Screening for 300 Designer Drugs and Metabolites, Tuesday,
Feb. 26 at 9 a.m. and 1 p.m. EST: Dr. Tony DiCaprio of Florida
International University's Forensic Science Institute will describe
current work focusing on the development of LC-QQQ-MS/MS-based methods
for rapid screening of designer drugs in forensic analysis.
GC/MS and GC/QQQ Screening for 300 Designer Drugs and Metabolites, Thursday,
April 18 at 9 a.m. and 1 p.m. EST: Dr. Jose Almirall, also of Florida
International University's Forensic Science Institute, will focus on the
expanded Designer Drug Library that FIU has developed in partnership
with Agilent; discussion will also focus on the entire workflow for
effective and rapid screening of designer drugs.
Webinar co-sponsor RTI International is the Center of Excellence for the
United States National Institute of Justice. The upcoming webinars are
part of RTI's specialized forensic education service, which provides
online forensic science training and continuing education courses to
practitioners in forensic science, law enforcement, medico-legal death
investigation and forensic toxicology.
About NMS Labs
NMS Labs (www.nmslabs.com)
based in Willow Grove, Pa., is the nation's premiere independent
clinical toxicology and diagnostic laboratory, backed by a comprehensive
list of accreditations and a team of more than 200 scientific staff. A
national reference laboratory, it offers more than 2,500 assays that
test for commonly abused and therapeutic drugs, environmental agents,
metals and more.
About Immunalysis Corporation
Immunalysis Corporation (www.immunalysis.com)
develops, manufactures and markets immunoassay reagents for the
screening of drugs of abuse and other small molecules in a variety of
biological matrices. The company draws upon its expertise in organic
chemistry, immunology, biochemistry, assay development and quality
control to supply immunoassay reagents and validated automation options.
This combination provides forensic toxicologists with powerful complete
drug screening solutions to meet the challenges demanded by alternative
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement
company and a technology leader in chemical analysis, life sciences,
diagnostics, electronics and communications. The company's 20,500
employees serve customers in more than 100 countries. Agilent had
revenues of $6.9 billion in fiscal 2012. Information about Agilent is
available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.
[ Back To TMCnet.com's Homepage ]